BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil.

The aim of this study was to evaluate a prognostic score for aids-related lymphoma (ARL).

Diffuse large B-cell lymphoma (DLBC) was the most observed histological type (79.8%).

The median CD4 lymphocyte count at lymphoma diagnosis was 125 cells per microliter.

The survival risk factors observed in multivariate analysis (previous AIDS and high-intermediate/high international prognostic index (IPI)) were combined to construct a risk score, which divided the whole patient population in three distinct groups as low, intermediate, and high risk.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell. 2007 Mar 23;128(6):1173-86 [17382885.001]

[Cites] Br J Haematol. 2007 Mar;136(5):762-4 [17313379.001]

[Cites] J Thromb Haemost. 2006 Dec;4(12):2656-63 [16961585.001]

[Cites] Br J Haematol. 2006 Apr;133(1):78-82 [16512832.001]

[Cites] Eur J Haematol. 2002 May;68(5):253-61 [12144531.001]

[Cites] J Clin Invest. 2005 Jan;115(1):155-60 [15630455.001]

[Cites] Platelets. 2008 Mar;19(2):96-103 [18297548.001]

[Cites] Transfus Apher Sci. 2003 Jun;28(3):285-95 [12725956.001]

[Cites] Blood. 2003 May 1;101(9):3708-13 [12506021.001]

[Cites] Blood. 2003 Feb 15;101(4):1658-9; author reply 1659 [12560247.001]

[Cites] Lab Invest. 2009 Apr;89(4):374-84 [19238135.001]

[Cites] Br J Haematol. 2008 Jul;142(3):494-7 [18492095.001]

[Cites] J Thromb Haemost. 2008 Oct;6(10):1780-8 [18665919.001]

[Cites] Biochem Biophys Res Commun. 2004 Jul 23;320(2):303-10 [15219827.001]

(PMID = 19495752.001).

[ISSN] 1432-0584

[Journal-full-title] Annals of hematology

[ISO-abbreviation] Ann. Hematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Other-IDs] NLM/ PMC2900585

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034.

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) represents a clinically heterogeneous disease.

PATIENTS AND METHODS: We examined 81 DLBCLs from patients with AIDS in AMC010 (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] v CHOP-rituximab) and AMC034 (etoposide, doxorubicin, vincristine, prednisone, and dose-adjusted cyclophosphamide plus rituximab concurrent v sequential) clinical trials and compared the immunophenotype with survival data, Epstein-Barr virus (EBV) positivity, and CD4 counts.

Expression of FOXP1, Blimp-1/PRDM1, or BCL-2 was not correlated with the outcome in patients with AIDS-related DLBCL.

CONCLUSION: These data indicate that with current treatment strategies for lymphoma and control of HIV infection, commonly used immunohistochemical markers may not be clinically relevant in HIV-infected patients with DLBCL.

[MeSH-major] Immunophenotyping. Ki-67 Antigen. Lymphoma, AIDS-Related / immunology. Lymphoma, Large B-Cell, Diffuse / immunology

[MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Proliferation. Humans. Immunohistochemistry. Prognosis. Survival Analysis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]

[Cites] Oncology (Williston Park). 2002 Apr;16(4):441-51, 456, 459 [12017534.001]

[Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]

[Cites] Blood. 2003 Mar 15;101(6):2363-7 [12424193.001]

[Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]

[Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]

[Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]

[Cites] Ann Hematol. 2004 Jul;83(7):414-9 [15085385.001]

[Cites] Blood. 2004 Nov 1;104(9):2933-5 [15238418.001]

[Cites] Blood. 1988 Apr;71(4):1157-60 [3281723.001]

[Cites] Lancet. 1991 Feb 9;337(8737):320-2 [1671232.001]

[Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]

[Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]

[Cites] Ann Oncol. 1994;5 Suppl 1:113-6 [8172807.001]

[Cites] Blood. 1997 Jan 15;89(2):601-9 [9002964.001]

[Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]

[Cites] J Clin Oncol. 1998 May;16(5):1931-9 [9586912.001]

[Cites] Leuk Lymphoma. 1998 Aug;30(5-6):515-24 [9711914.001]

[Cites] Clin Cancer Res. 2005 Feb 1;11(3):1065-72 [15709173.001]

[Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]

[Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]

[Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]

[Cites] J Clin Oncol. 2005 Dec 20;23(36):9067-72 [16172462.001]

[Cites] Mod Pathol. 2006 Mar;19(3):438-46 [16444194.001]

[Cites] Haematologica. 2006 Apr;91(4):467-74 [16585013.001]

[Cites] Microbes Infect. 2006 Apr;8(5):1301-7 [16697236.001]

[Cites] Clin Lymphoma Myeloma. 2006 May;6(6):455-7 [16796775.001]

[Cites] J Clin Oncol. 2006 Sep 1;24(25):4135-42 [16943530.001]

[Cites] Ann Oncol. 2007 May;18(5):931-9 [17395602.001]

[Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]

[Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]

[Cites] Histopathology. 2007 Jul;51(1):70-9 [17593082.001]

[Cites] Curr Opin Oncol. 2007 Sep;19(5):458-63 [17762571.001]

[Cites] Eur J Haematol. 2007 Dec;79(6):501-7 [17986209.001]

[Cites] Blood. 2008 Mar 1;111(5):2816-24 [18077790.001]

[Cites] Annu Rev Immunol. 2008;26:133-69 [18370921.001]

[Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]

[Cites] J Clin Oncol. 2008 Jun 1;26(16):2717-24 [18378569.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]

[Cites] Nat Rev Immunol. 2007 Dec;7(12):923-7 [17965637.001]

[Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]

[Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]

[Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]

[Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]

[Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]

[CommentIn] J Clin Oncol. 2010 Jun 1;28(16):e260; author reply e261-2 [20421532.001]

(PMID = 19752343.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / CA-121947

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Ki-67 Antigen

[Other-IDs] NLM/ PMC2799056

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles.

Based on gene expression profiling, diffuse large B-cell lymphomas arising in immunocompetent patients can be divided into germinal center and activated B-cell types.

Since little is known about acquired immunodeficiency syndrome associated diffuse large B-cell lymphomas, we tested whether the protein expression of germinal center and activated B-cell markers differed between acquired immunodeficiency syndrome (AIDS) vs non-AIDS diffuse large B-cell lymphomas.

We immunohistochemically stained tissue microarrays of 39 de novo diffuse large B-cell lymphomas: 12 AIDS associated and 27 non-AIDS, with germinal center (BCL6, CD10, CyclinH) and activated B-cell markers (MUM1, CD138, PAK1, CD44, BCL2).

The activated B-cell and germinal center summation scores of each case were used as (x, y) coordinate data points to construct two-dimensional contour-frequency plots.

The contour plot of non-AIDS diffuse large B-cell lymphomas showed two distinct clusters: a cluster with a high germinal center phenotype (cluster 1) and a cluster with a high activated B-cell phenotype (cluster 3).

In contrast, the AIDS-related diffuse large B-cell lymphomas formed a single aggregate (cluster 2) (P=0.02, Fisher exact test).

When the contour plots of the AIDS-related and the non-AIDS cases were superimposed, cluster 2 of the AIDS cases expressed an intermediate germinal center/activated B-cell phenotype compared to clusters 1 and 3 of the non-AIDS diffuse large B-cell lymphomas.

Our results confirm that non-AIDS diffuse large B-cell lymphomas segregate into two groups with either germinal center or activated B-cell phenotype.

We report the new finding that the AIDS status of the patient predicts the immunophenotype of the diffuse large B-cell lymphomas.

[MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - B-Cell Lymphomas.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16444194.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-myc; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.

This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20(+) diffuse large B-cell lymphoma.

There were no treatment-related deaths or new opportunistic infections during treatment, and patients had sustained CD4 cell count recovery and HIV viral control after treatment.

Tumor histogenesis was the only characteristic associated with lymphoma-specific outcome with 95% of germinal center B-cell (GCB) versus 44% of non-GCB diffuse large B-cell lymphoma (DLBCL) progression-free at 5 years.

However, new therapeutic advances are needed for non-GCB DLBCL, which remains the important cause of lymphoma-specific death.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18. HIV / physiology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Positron-Emission Tomography

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]

[Cites] AIDS. 2006 Apr 24;20(7):985-93 [16603850.001]

[Cites] N Engl J Med. 2006 Nov 30;355(22):2283-96 [17135583.001]

[Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]

[Cites] J Clin Oncol. 2007 Mar 1;25(7):805-12 [17327602.001]

[Cites] Science. 2008 Mar 21;319(5870):1676-9 [18323416.001]

[Cites] Blood. 2008 Apr 15;111(8):3986-90 [18172004.001]

[Cites] J Clin Oncol. 2008 Jun 1;26(16):2717-24 [18378569.001]

[Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]

[Cites] Curr Opin Oncol. 2008 Sep;20(5):522-8 [19106654.001]

[Cites] Blood. 2009 Jun 11;113(24):6069-76 [19380866.001]

[Cites] Crit Rev Oncol Hematol. 2009 Oct;72(1):10-20 [19070506.001]

[Cites] J Clin Oncol. 2009 Oct 20;27(30):5039-48 [19752343.001]

[Cites] Nature. 2006 May 4;441(7089):106-10 [16572121.001]

[Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]

[Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]

[Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]

[Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]

[Cites] Biochem Biophys Res Commun. 2001 Dec 21;289(5):1199-204 [11741320.001]

[Cites] Blood. 2002 Apr 15;99(8):2685-93 [11929754.001]

[Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]

[Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]

[Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]

[Cites] Lancet. 2003 Sep 20;362(9388):959-61 [14511930.001]

[Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]

[Cites] Mol Cancer Ther. 2004 May;3(5):621-32 [15141020.001]

[Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]

[Cites] Blood. 1997 Jan 15;89(2):601-9 [9002964.001]

[Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]

[Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]

[Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Blood. 2006 Apr 1;107(7):3014-5 [16554492.001]

[CommentIn] Blood. 2010 Apr 15;115(15):2986-7 [20395421.001]

(PMID = 20130244.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00019253

[Publication-type] Clinical Trial, Phase II; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol

[Other-IDs] NLM/ PMC2858473

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.

We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL).

Reduced VEGF protein expression in primary HIV-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines.

Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Med. 1996 Dec;2(12):1371-5 [8946838.001]

[Cites] Oncogene. 2000 Jan 20;19(3):373-9 [10656684.001]

[Cites] Oncogene. 1996 Jan 18;12(2):289-97 [8570206.001]

[Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]

[Cites] Leuk Lymphoma. 2007 Oct;48(10):2014-21 [17917969.001]

[Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]

[Cites] Exp Cell Res. 2007 May 1;313(8):1561-74 [17382929.001]

[Cites] Am J Pathol. 2007 Apr;170(4):1362-9 [17392174.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52 [17360578.001]

[Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):693-9 [17320821.001]

[Cites] Nat Struct Mol Biol. 2007 Mar;14(3):249-50 [17293873.001]

[Cites] J Cell Biochem. 2007 Feb 15;100(3):727-37 [17115409.001]

[Cites] Curr Med Chem. 2006;13(16):1845-57 [16842197.001]

[Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]

[Cites] Folia Histochem Cytobiol. 2004;42(4):241-3 [15704651.001]

[Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]

[Cites] Circulation. 1997 Dec 2;96(11):4083-94 [9403634.001]

[Cites] J Biol Chem. 1998 Nov 20;273(47):31119-24 [9813014.001]

[Cites] Science. 1998 Dec 4;282(5395):1837-9 [9874635.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]

[Cites] J Clin Pathol. 1997 Jun;50(6):481-4 [9378813.001]

[Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]

[Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]

[Cites] Nature. 1994 Oct 20;371(6499):674-80 [7935812.001]

[Cites] Arch Orthop Trauma Surg. 2003 Nov;123(9):475-80 [12750926.001]

[Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]

[Cites] Cell Prolif. 2003 Jun;36(3):131-49 [12814430.001]

[Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]

[Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]

[Cites] J Rheumatol. 2003 Feb;30(2):260-8 [12563678.001]

[Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]

[Cites] Hum Pathol. 2002 Jul;33(7):723-31 [12196924.001]

[Cites] Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44 [11965229.001]

[Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]

[Cites] Am J Clin Pathol. 2001 Dec;116(6):838-45 [11764072.001]

[Cites] Biochem J. 2001 Feb 1;353(Pt 3):569-78 [11171054.001]

[Cites] Cancer Res. 2001 Jan 15;61(2):462-8 [11212232.001]

[Cites] Curr Opin Oncol. 2000 Sep;12(5):445-9 [10975552.001]

[Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71 [10873597.001]

[Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]

[Cites] Am J Pathol. 1996 Apr;148(4):1065-74 [8644848.001]

(PMID = 19669199.001).

[ISSN] 1868-9256

[Journal-full-title] Journal of hematopathology

[ISO-abbreviation] J Hematop

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Other-IDs] NLM/ PMC2712328

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.

BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.

In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.

Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.

OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.

The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.

Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.

These findings were not related to age, sex or type of lymphoma.

There was no association of HHV-8 with the lymphoma cells.

CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.

[MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology

[MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]

[Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]

[Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]

[Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]

[Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]

[Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]

[Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]

[Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]

[Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]

[Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]

[Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]

[Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]

[Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]

[Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]

[Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]

[Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]

[Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]

[Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]

[Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]

[Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]

[Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]

[Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]

[Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]

[Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]

[Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]

[Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]

[Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]

[Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

(PMID = 16916294.001).

[ISSN] 1729-0503

[Journal-full-title] African health sciences

[ISO-abbreviation] Afr Health Sci

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Uganda

[Other-IDs] NLM/ PMC1831982

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma.

BACKGROUND: Plasmablastic lymphoma (PL) is a subtype of diffuse large B-cell lymphoma (DLBCL).

Studies have suggested that tumors with PL morphology represent a group of neoplasms with clinopathologic characteristics corresponding to different entities including extramedullary plasmablastic tumors associated with plasma cell myeloma (PCM).

The goal of the current study was to evaluate the genetic similarities and differences among PL, DLBCL (AIDS-related and non AIDS-related) and PCM using array-based comparative genomic hybridization.

This correlated with segmental gains occurring in high frequency in DLBCL (AIDS-related and non AIDS-related) cases.

There were some segmental gains and some segmental loss that occurred in PL but not in the other types of lymphoma suggesting that these foci may contain genes responsible for the differentiation of this lymphoma.

Additionally, some segmental gains and some segmental loss occurred only in PL and AIDS associated DLBCL suggesting that these foci may be associated with HIV infection.

Furthermore, some segmental gains and some segmental loss occurred only in PL and PCM suggesting that these lesions may be related to plasmacytic differentiation.

The genomic aberration pattern of PL appears to be more similar to that of DLBCL (AIDS-related or non AIDS-related) than to PCM.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] BMC Cancer. 2004 Aug 7;4:45 [15298715.001]

[Cites] Nat Genet. 2004 Mar;36(3):299-303 [14981516.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1;16(1):1-9 [9377118.001]

[Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]

[Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]

[Cites] Blood. 2006 Mar 15;107(6):2477-85 [16317097.001]

[Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]

[Cites] Neoplasia. 2008 Jan;10(1):89-98 [18231642.001]

[Cites] Mod Pathol. 2008 May;21(5):599-608 [18246049.001]

[Cites] J Neurooncol. 2008 Jul;88(3):281-91 [18398573.001]

[Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]

[Cites] FEBS Lett. 2000 Jan 28;466(2-3):367-71 [10682862.001]

[Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]

[Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]

[Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]

[Cites] J Hepatol. 2003 Mar;38(3):298-306 [12586295.001]

[Cites] Clin Lymphoma. 2003 Sep;4(2):86-92 [14556679.001]

[Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]

(PMID = 19909553.001).

[ISSN] 1756-8722

[Journal-full-title] Journal of hematology & oncology

[ISO-abbreviation] J Hematol Oncol

[Language] ENG

[Grant] United States / NLM NIH HHS / LM / R01 LM010185; United States / NIDCR NIH HHS / DE / DE017086

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Other-IDs] NLM/ PMC2789747

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma.

[MeSH-major] Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] J Clin Oncol. 2009 Oct 20;27(30):5039-48 [19752343.001]

(PMID = 20421532.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comment; Letter

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.

Morphologic features of Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) overlap.

We tested a panel of 8 germinal center (GC) and activated B-cell (ABC) markers for their ability to separate BL and DLBCL.

We diagnosed 16 BL and 39 DLBCL cases from 21 patients with AIDS and 34 without AIDS based on traditional morphologic criteria, Ki-67 proliferative index, and c-myc rearrangement (fluorescence in situ hybridization).

[MeSH-major] B-Lymphocytes / immunology. Burkitt Lymphoma / pathology. Germinal Center / immunology. Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16203284.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.

Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.

Within a cohort of 99 HIV-related NHLs, 10 cases were found to be KSHV positive on the basis of immunostaining for KSHV LNA-1 as well as KSHV-specific polymerase chain reaction.

Interestingly, all KSHV-positive cases belonged to a distinctive subgroup of 26 diffuse large B-cell lymphomas characterized by the expression of CD138 (syndecan-1) and plasmablastic/immunoblastic morphology.

Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-related solid immunoblastic/plasmablastic lymphomas.

[MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15744337.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.

PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.

PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).

RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Steroids.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. LEUCOVORIN .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Clin Oncol. 2005 Nov 20;23(33):8538-40; author reply 8540-1 [16293885.001]

[CommentIn] J Clin Oncol. 2005 Nov 1;23(31):8132-3; author reply 8133-4 [16258119.001]

(PMID = 15883411.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; M-BACOD protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib.

An AIDS-defining illness, PBL comprises 2.6% of AIDS-related lymphomas.

They are terminally differentiated B-cell neoplasms, and typically lack common B-cell markers but uniformly express plasma cell markers.

A 42-year-old male with newly diagnosed AIDS presented with nausea, vomiting, bloody diarrhea and epigastric pain.

Flow cytometry was negative for CD45 and all common epithelial, T-cell and B-cell markers, but was positive for CD138 and p63(VS38c).

The WHO classifies PBL as a variant of diffuse large B-cell lymphoma.

However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms.

Bortezomib is a proteasome inhibitor widely used in multiple myeloma and mantle cell lymphoma.

We chose bortezomib based on our patient's poor performance status and immune function, the desire to avoid combination chemotherapy, and translocations involving the immunoglobulin heavy chain gene locus (8;14) similar to those seen in multiple myeloma(4;14, 14;16) and mantle cell lymphoma(11;14).

A shift in the paradigm of treatment of PBL towards agents effective in plasma cell malignancies may be necessary.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961065.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary testicular lymphoma and AIDS.

Immunosuppressed patients have an increased risk for developing extranodal lymphoma, including testicular lymphoma.

In AIDS patients, primary testicular lymphoma has been reported as an initial manifestation of the disease.

We report a testicular lymphoma consistent with diffuse large B-cell lymphoma (DLBCL) in an AIDS patient and we review the literature on primary testicular lymphoma in AIDS patients.

[MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Testicular Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20124334.001).

[ISSN] 1550-8080

[Journal-full-title] Annals of clinical and laboratory science

[ISO-abbreviation] Ann. Clin. Lab. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.

PURPOSE: To compare the prognostic factors for survival and the validity of the International Prognostic Index (IPI) in patients with HIV-related diffuse large-cell lymphoma (HIV-DLCL) treated with curative intent in the pre-highly active antiretroviral therapy (HAART) era versus the HAART era.

RESULTS: There were no statistically significant differences in terms of either lymphoma or HIV-related characteristics in the two time periods.

Clinical outcomes in patients with HIV-DLCL are now approaching the outcomes of patients with de novo lymphoma.

[MeSH-major] Antiretroviral Therapy, Highly Active. Health Status Indicators. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16230675.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma (DLBCL) represents the most common form of monomorphic PTLD.

[MeSH-major] Lymphoma, Large B-Cell, Diffuse / genetics. Organ Transplantation / adverse effects. Polymorphism, Single Nucleotide

[MeSH-minor] Comparative Genomic Hybridization. DNA, Neoplasm / genetics. Gene Expression Profiling / methods. Genetic Predisposition to Disease. Humans. Immunocompromised Host. Loss of Heterozygosity. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / immunology. Recurrence

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

MedlinePlus Health Information. consumer health - Organ Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20230398.001).

[ISSN] 1365-2141

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Neoplasm

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Management of AIDS-related lymphoma.

PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.

Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.

High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.

Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.

Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.

[MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19106654.001).

[ISSN] 1531-703X

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 48

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.

In the era of highly active antiretroviral treatment (HAART), the prognosis of AIDS-related lymphomas might be similar to that of aggressive B-cell lymphomas in human immunodeficiency (HIV)-negative patients.

In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15921395.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Letter; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy.

Anaplastic large-cell lymphoma (ALCL) has rarely been described in patients with acquired immunodeficiency syndrome (AIDS).

Reports of treatment of ALCL in the setting of AIDS are rare as well.

Dose-adjusted EPOCH (DA-EPOCH; etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) has been shown to be well tolerated and effective in the treatment of AIDS-related aggressive B-cell lymphomas.

Treatment of AIDS-associated ALCL with DA-EPOCH has not been reported.

This report describes two patients with AIDS-associated ALCL treated with DA-EPOCH chemotherapy.

Our experience suggests that DA-EPOCH is an effective treatment for AIDS-associated ALCL.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.

Genetic Alliance. consumer health - Lymphoma, large-cell.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]

[Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]

[Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]

[Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]

[Cites] Blood. 1995 Sep 1;86(5):1694-700 [7655001.001]

[Cites] Cancer. 1993 Nov 15;72(10):3078-90 [8221575.001]

[Cites] Am J Surg Pathol. 1988 Apr;12(4):264-74 [3354752.001]

[Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]

[Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]

[Cites] Ai Zheng. 2004 Aug;23(8):943-6 [15301720.001]

(PMID = 17668647.001).

[ISSN] 1943-4693

[Journal-full-title] Journal of the National Medical Association

[ISO-abbreviation] J Natl Med Assoc

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol

[Other-IDs] NLM/ PMC2574342

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada.

OBJECTIVE: To examine the influence of the AIDS epidemic on the incidence of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) in Ontario.

AIDS cases were extracted from Ontario Ministry of Health and Long-Term Care reports.

CONCLUSIONS: The AIDS epidemic, the introduction of antiretroviral therapies, and the decrease in HIV infection rates explain the rise and decline of KS incidence in Ontario.

NHL incidence trends are more complex, although the AIDS epidemic explains the trends observed in younger men (in whom AIDS is more common), and for the AIDS-related subtypes.

[MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Population Surveillance. Sarcoma, Kaposi / epidemiology

[MeSH-minor] Adult. Burkitt Lymphoma / epidemiology. Humans. Incidence. Logistic Models. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large-Cell, Immunoblastic / epidemiology. Male. Ontario / epidemiology. Registries / statistics & numerical data. Retrospective Studies

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18618279.001).

[ISSN] 1573-7225

[Journal-full-title] Cancer causes & control : CCC

[ISO-abbreviation] Cancer Causes Control

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long-term complete regression of nodal marginal zone lymphoma transformed into diffuse large B-cell lymphoma with highly active antiretroviral therapy alone in human immunodeficiency virus infection.

Since the introduction of combination antiretroviral therapy (cART), there has been a decrease in the incidence of non-Hodgkin lymphoma among the HIV-infected population and also significantly improved survival rates.

We describe a remarkable case of a HIV-infected patient whose large B-cell lymphoma, most likely arising by transformation of a nodal marginal zone lymphoma, completely regressed with the use of cART alone.

He remained disease-free for almost 3 years and he finally died from presumed flare up of his lymphoma.

This is an extreme example of the significance of cART in improving survival in HIV-non-Hodgkin lymphoma and changing the face of the HIV epidemic in general.

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, B-Cell, Marginal Zone / complications. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20010159.001).

[ISSN] 1538-2990

[Journal-full-title] The American journal of the medical sciences

[ISO-abbreviation] Am. J. Med. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 31

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.

Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma.

This phase II trial aimed to evaluate the safety and efficacy of six cycles of R-CHOP in patients with HIV-related DLBCL and to determine whether response to highly active antiretroviral therapy (HAART) had prognostic impact.

In HIV-related DLBCL R-CHOP is feasible, safe and effective.

The prognosis depends on lymphoma-related parameters and on the response to HAART.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18162120.001).

[ISSN] 1365-2141

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Morphological spectrum of AIDS-related plasmablastic lymphomas.

We have had a recent spurt in cases of AIDS-related lymphoma (ARL) at our centre.

Most of these cases are aggressive mature B cell lymphomas, mainly plasmablastic lymphoma (PBL) and diffuse large B-cell lymphoma (DLBCL).

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunoglobulin Light Chains / analysis. Leukemia, Plasma Cell / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Syndecan-1 / analysis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18417882.001).

[ISSN] 0377-4929

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Light Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; EC 3.1.3.48 / Antigens, CD45

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary mediastinal large B-cell lymphoma in an HIV-infected patient.

HIV-related non-Hodgkin lymphoma is well documented in the literature.

We report a case of an HIV-infected patient who presents with primary mediastinal large B-cell lymphoma.

On review of the literature, this appears to be the first documented case of this subtype of large B-cell non-Hodgkin lymphoma seen in an HIV-infected patient.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis

Genetic Alliance. consumer health - HIV.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15767818.001).

[ISSN] 0002-9629

[Journal-full-title] The American journal of the medical sciences

[ISO-abbreviation] Am. J. Med. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.

OBJECTIVE: To describe the antiretroviral management of a patient diagnosed simultaneously with HIV/AIDS and diffuse large B-cell lymphoma, focusing on the drug-drug interactions between highly active antiretroviral therapy (HAART) and concomitant cancer chemotherapy.

CASE SUMMARY: A 55-year-old white man was recently diagnosed with HIV/AIDS and presented 1 month later with complaints of nausea, vomiting, abdominal pain, double vision, right eye discomfort/swelling, and a 3.6-kg weight loss.

An excisional biopsy of a right inguinal lymph node confirmed a new diagnosis of diffuse large B-cell lymphoma.

DISCUSSION: HAART improves the chemotherapeutic response in patients with HIV and lymphoma.

[MeSH-minor] Antiretroviral Therapy, Highly Active / methods. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Drug Interactions. HIV Integrase Inhibitors / therapeutic use. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / etiology. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / therapeutic use. Raltegravir Potassium. Vincristine / therapeutic use

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. Raltegravir .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. METHOTREXATE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20040700.001).

[ISSN] 1542-6270

[Journal-full-title] The Annals of pharmacotherapy

[ISO-abbreviation] Ann Pharmacother

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / HIV Integrase Inhibitors; 0 / Pyrrolidinones; 43Y000U234 / Raltegravir Potassium; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiation therapy for HIV-associated diffuse large cell non-Hodgkin lymphoma.

PURPOSE: To report the clinical experience with external beam radiotherapy (RT) for AIDS-related lymphoma (ARL) with or without the involvement of the central nervous system (CNS) in HIV-infected patients.

[MeSH-major] Lymphoma, AIDS-Related / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19589920.001).

[ISSN] 1545-1097

[Journal-full-title] Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)

[ISO-abbreviation] J Int Assoc Physicians AIDS Care (Chic)

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy.

Recent introduction of highly active antiretroviral therapy (HAART) is reported to have reduced the incidence of lymphoma among HIV-infected individuals.

A clinicopathological study was performed on 86 AIDS-related lymphoma patients who were treated in Tokyo area from 1987 to 2005.

The incidence of lymphoma detected by autopsy was 27% (53 cases/198 autopsies).

Diffuse large B cell lymphoma was the most predominant histological subtype throughout the period (78%).

Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users.

Epstein-Barr virus (EBV)-positive lymphoma decreased from 88% in the pre-HAART era to 58% in the HAART era, but did not differ significantly between HAART users (73%) and non-users (74%).

Nodal involvement of lymphoma increased from 14% in the pre-HAART era to 50% in the HAART era; however, central nervous system involvement decreased from 62 to 38%.

These data suggest that HAART might play a partial role in these changes, and the alteration in immunological backgrounds, such as EBV prevalence, is suggested as another leading cause of these changes in Japanese AIDS-related lymphoma.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16697236.001).

[ISSN] 1286-4579

[Journal-full-title] Microbes and infection

[ISO-abbreviation] Microbes Infect.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autologous stem-cell transplantation in patients with HIV-related lymphoma.

PURPOSE: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure.

RESULTS: Since 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18).

CI of relapse was 30.4% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3).

CONCLUSION: Similarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3263

(PMID = 19332732.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Isolated cranial nerve III palsy as the presenting manifestation of HIV-related large B-cell lymphoma: clinical, radiological and postmortem observations: report of a case and review of the literature.

Rarely can a neurologically isolated cranial nerve III palsy be the presenting manifestation of central nervous system lymphoma.

We detail the clinical, radiological, and pathological features of a previously healthy 45-year-old man presenting with an isolated, pupil-involving, right cranial nerve III palsy due to human immunodefiency virus (HIV) related non-Hodgkin lymphoma.

Morphologic and flow cytometric analysis of the cerebrospinal fluid was compatible with a large B-cell lymphoma.

Postmortem examination of the brain revealed malignant lymphomatous cell infiltration of both cranial nerve III, diffuse leptomeningeal disease and focal superficial subependymal and subpial invasion.

Based on our review of the literature, we were able to find only 10 detailed cases of cranial nerve III palsy as the presenting manifestation of central nervous system lymphoma.

[MeSH-major] HIV / immunology. HIV Antibodies / immunology. Lymphoma, AIDS-Related / complications. Magnetic Resonance Imaging. Oculomotor Nerve Diseases / etiology. Tomography, X-Ray Computed

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - CT Scans.

MedlinePlus Health Information. consumer health - MRI Scans.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16263372.001).

[ISSN] 0039-6257

[Journal-full-title] Survey of ophthalmology

[ISO-abbreviation] Surv Ophthalmol

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / HIV Antibodies

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful treatment with autologous peripheral blood stem cell transplantation for acquired immunodeficiency syndrome (AIDS)-related malignant lymphoma.

Histologic diagnosis of a biopsied lymph node was diffuse, large, B cell-type malignant lymphoma.

The karyotype of the lymphoma cells was t(8;14)(q24;q32), which was confirmed by G-banding and fluorescent in situ hybridization.

The clinical stage of the lymphoma was IVB and the international prognosis index was categorized as high.

Complete remission (CR) of the lymphoma was obtained after 2 courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) chemotherapy and 4 subsequent courses of rituximab-combined CHOP (R-CHOP).

Because of the poor prognosis of AIDS-related lymphoma, he received autologous peripheral blood stem cell transplantation with the MEAM protocol (ranimustine, etoposide, cytarabine, melphalan) as a conditioning procedure without a severe infectious episode.

[MeSH-major] Lymphoma, AIDS-Related / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Transplantation.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20009441.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.

BACKGROUND: Non-Hodgkin lymphoma (NHL) associated with HIV became an AIDS-defining condition early in the epidemic and remains the second most common malignancy in patients with AIDS.

With the advent of highly active antiretroviral therapy (HAART), the incidence and mortality of AIDS-related opportunistic infections and Kaposi's sarcoma has fallen dramatically, this trend is not observed so clearly for NHL.

Our objective was to review the clinical spectrum of patients with AIDS-associated NHL and to analyze the impact of HAART on survival at an oncological tertiary center.

RESULTS: Eighty seven HIV-positive patients were diagnosed with NHL (diffuse large B-cell lymphoma n=69; Burkitt-like n=8; pleomorphic large cell n=7; low-grade n=2, and angiocentric n=1).

[MeSH-major] Cancer Care Facilities / statistics & numerical data. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19227434.001).

[ISSN] 0034-8376

[Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición

[ISO-abbreviation] Rev. Invest. Clin.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Mexico

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphomas: from pathogenesis to pathology.

The vast majority of these lymphomas are high-grade B-cell lymphomas: Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) with centroblastic (CB) features and DLBCL with immunoblastic (IBL) features;.

(2) unusual lymphomas occurring more specifically in HIV-positive patients and include two rare entities, namely 'primary effusion lymphoma' (PEL) and 'plasmablastic lymphoma' of the oral cavity.

The pathological heterogeneity of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas (AIDS-NHL) reflects the heterogeneity of their associated molecular lesions.

In AIDS-BL, the molecular lesions involve activation of cMYC, inactivation of P53, and infection with Epstein-Barr virus (EBV).

AIDS-IBL infected with EBV are characterised by frequent expression of latent membrane protein 1--an EBV oncoprotein.

The biological heterogeneity of AIDS-NHL is highlighted by their histogenetic differences.

Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8)-associated lymphomas, which often develop in persons with advanced AIDS, present predominantly as PEL.

(2) extracavitary and arise in nodal and/or extranodal sites; and (3) histologically, they usually display a PEL-like morphology and plasma cell-related phenotype.

[MeSH-major] HIV-1. Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin. Sarcoma, Kaposi

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16115121.001).

[ISSN] 0007-1048

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Number-of-references] 53

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genome wide DNA-profiling of HIV-related B-cell lymphomas.

To elucidate HIV-NHL pathogenesis, we performed a genome-wide DNA profiling based on a single nucleotide polymorphism-based microarray comparative genomic hybridization in 57 HIV-lymphomas and, for comparison, in 105 immunocompetent diffuse large B-cell lymphomas (IC-DLBCL).

HIV-Burkitt lymphoma showed a significantly lower number of lesions than HIV-DLBCL (P = 0.032), whereas the median number of copy number changes was significantly higher in Epstein-Barr virus negative (EBV-) HIV-DLBCL (42.5, range 8-153) compared to EBV+ cases (22; range 3-41; P = 0.029).

[MeSH-major] Lymphoma, AIDS-Related / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Polymorphism, Single Nucleotide

[MeSH-minor] Burkitt Lymphoma / genetics. Chromosome Aberrations. DNA Methylation. Gene Frequency. Humans. Microarray Analysis. Polymerase Chain Reaction / methods

Genetic Alliance. consumer health - B-Cell Lymphomas.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oncogene. 2004 Dec 2;23(56):9148-54 [15480422.001]

[Cites] Br J Haematol. 2006 Jul;134(1):27-36 [16803564.001]

[Cites] Cancer Lett. 2006 Jan 28;232(1):37-47 [16242840.001]

[Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]

[Cites] Semin Cancer Biol. 2007 Feb;17(1):31-41 [17140807.001]

[Cites] Cancer Lett. 2007 Jul 18;252(2):157-70 [17188425.001]

[Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]

[Cites] Blood. 2008 Feb 15;111(4):2347-53 [18079361.001]

[Cites] Cancer Lett. 2006 Jan 28;232(1):48-57 [16221525.001]

[Cites] Am J Hum Genet. 1992 Jun;50(6):1243-51 [1317992.001]

[Cites] Haematologica. 2008 Aug;93(8):1178-85 [18556404.001]

[Cites] J Biol Chem. 2006 Mar 31;281(13):8591-9 [16455660.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3615-20 [11891319.001]

[Cites] AIDS. 2006 Nov 28;20(18):2285-91 [17117014.001]

[Cites] Int J Cancer. 2005 Sep 1;116(3):407-14 [15818620.001]

[Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]

[Cites] J Cell Physiol. 2007 Aug;212(2):307-10 [17458891.001]

[Cites] Oncogene. 2003 Feb 27;22(8):1225-37 [12606949.001]

[Cites] Mol Cancer Res. 2003 Nov;1(13):940-7 [14638866.001]

[Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] Front Biosci. 2007 Sep 01;12:4911-24 [17569619.001]

[Cites] Blood. 2006 Mar 15;107(6):2477-85 [16317097.001]

[Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Nat Cell Biol. 2003 Mar;5(3):216-23 [12598906.001]

[Cites] Nature. 2009 Jun 4;459(7247):717-21 [19412164.001]

[Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]

[Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]

[Cites] PLoS Comput Biol. 2006 May;2(5):e41 [16699594.001]

[Cites] Nat Rev Cancer. 2004 Dec;4(12):978-87 [15573119.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1270-5 [11423258.001]

[Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1129-36 [17823927.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]

[Cites] Cancer Res. 2008 Apr 15;68(8):2610-21 [18375840.001]

[Cites] Cell Cycle. 2007 May 2;6(9):1044-8 [17457056.001]

[Cites] BMC Bioinformatics. 2009 Jan 08;10:10 [19133123.001]

[Cites] Int J Cancer. 2006 Apr 15;118(8):1945-53 [16287063.001]

[Cites] Cancer Res. 2001 Nov 15;61(22):8068-73 [11719429.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1031-6 [11355876.001]

[Cites] Genes Chromosomes Cancer. 2004 Dec;41(4):321-9 [15384174.001]

[Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10 ):5956-61 [12719539.001]

[Cites] Nat Rev Immunol. 2009 Apr;9(4):235-45 [19319142.001]

[Cites] Br J Haematol. 2008 May;141(5):622-30 [18397341.001]

[Cites] Oncogene. 2005 Feb 24;24(9):1625-33 [15674328.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] Lab Invest. 2004 Sep;84(9):1193-9 [15241441.001]

[Cites] Cell Death Differ. 2005 Aug;12(8):1031-43 [16015380.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3949-54 [17360458.001]

[Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]

[Cites] Cancer Genet Cytogenet. 2006 Dec;171(2):119-21 [17116491.001]

[Cites] J Neurochem. 2008 Jun;105(5):1806-19 [18248624.001]

(PMID = 19832807.001).

[ISSN] 1365-2141

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / U01 CA114778-05; United States / NCI NIH HHS / CA / UO1 CA 114778

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV lumbosacral radiculoplexus neuropathy mimicking lymphoma: diffuse infiltrative lymphocytosis syndrome (DILS) restricted to nerve?

Diffuse infiltrative lymphocytosis syndrome (DILS) is a hyperimmune reaction against HIV.

It leads to MHC-restricted clonal expansion of CD8 T cells characterized by circulating CD8 hyperlymphocytosis and CD8 T-cell infiltration in organs.

Nerve biopsy showed large collections of CD8 lymphocytes suspicious for lymphoma.

[MeSH-major] AIDS-Associated Nephropathy / diagnosis. Lymphocytosis / diagnosis. Lymphoma, AIDS-Related / diagnosis. Radiculopathy / diagnosis

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Muscle Nerve. 2002 Apr;25(4):477-91 [11932965.001]

[Cites] J Neuropathol Exp Neurol. 2008 Aug;67(8):819-27 [18648321.001]

[Cites] Mayo Clin Proc. 1975 Nov;50(11):621-37 [1186294.001]

[Cites] Ann Neurol. 1980 Dec;8(6):590-6 [7212646.001]

[Cites] Ann Neurol. 1987 Jan;21(1):32-40 [3030188.001]

[Cites] Cancer. 1988 Jun 1;61(11):2318-24 [3365659.001]

[Cites] Lancet. 1989 Aug 26;2(8661):466-8 [2570184.001]

[Cites] Ann Intern Med. 1990 Jan 1;112(1):3-10 [2136714.001]

[Cites] Rheum Dis Clin North Am. 1992 Aug;18(3):683-97 [1496168.001]

[Cites] J Clin Invest. 1993 Jul;92(1):495-502 [8392093.001]

[Cites] Ann Neurol. 1994 Jan;35(1):53-8 [8285593.001]

[Cites] AIDS. 1996 Apr;10(4):385-91 [8728042.001]

[Cites] Ann Neurol. 1997 Apr;41(4):438-45 [9124800.001]

[Cites] Neurology. 1998 Apr;50(4):855-7 [9566362.001]

[Cites] Neurology. 1998 Apr;50(4):1041-4 [9566392.001]

[Cites] Mayo Clin Proc. 2006 Feb;81(2):213-9 [16471077.001]

[Cites] Neuromuscul Disord. 2004 Nov;14(11):740-3 [15482959.001]

(PMID = 19882634.001).

[ISSN] 1097-4598

[Journal-full-title] Muscle & nerve

[ISO-abbreviation] Muscle Nerve

[Language] eng

[Grant] United States / NINDS NIH HHS / NS / R01 NS036797; United States / NINDS NIH HHS / NS / R01 NS036797-12

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Other-IDs] NLM/ NIHMS235321; NLM/ PMC2965045

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Behaviour of HIV/AIDS-related lymphoma in Pedro Kouri Institute. 2004-2005].

A prospective and descriptive study of 20 patients infected with HIV and admitted to "Pedro Kouri" Institute of Tropical Disease after a diagnosis of lymphoma was conducted.

Of this number, 85% presented with CD4+ count under 350 cell/mm3 at the time of diagnosis; however, only 55% showed viral loads exceeding 50,000 copies/mL.

The predominant histological subtype was large diffuse cells and the most frequent location was the extrapulmonary site in 70% of cases.

It called our attention that high levels of lactic acid dehydrogenase and extrapulmonary location of tumors were related.

Statistically significant association was found (p < 0.05) between immunosuppresion condition of the patients given by CD4+ count below 350 cell/mm3 and advanced staging of the tumoral disease (stages III and IV).

[MeSH-major] Lymphoma, AIDS-Related / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 23424794.001).

[ISSN] 0375-0760

[Journal-full-title] Revista cubana de medicina tropical

[ISO-abbreviation] Rev Cubana Med Trop

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Cuba

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.

OBJECTIVES: To assess complete remission (CR) and survival in patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) receiving highly active antiretroviral therapy (HAART).

Histologic subtypes were diffuse large B-cell lymphoma (DLCL; n = 153 [72.9%]), Burkitt and atypical Burkitt/Burkitt-like lymphoma (BL; n = 40 [19.0%]), T-cell lymphoma (TC; n = 8 [3.8%]), and miscellaneous (n = 9 [4.3%]).

CONCLUSIONS: In patients with ARL treated with HAART, CR was associated exclusively with tumor-related factors.

[MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Longitudinal Studies. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Remission Induction. Statistics as Topic. Survival Analysis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17117144.001).

[ISSN] 1525-4135

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-HIV Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphoproliferative disease.

Not long after the recognition of HIV as the causative agent of AIDS, it was evident that individuals infected with HIV developed lymphoma at a greater rate than the population at large.

Approximately two thirds of AIDS-related lymphoma (ARL) cases are categorized as diffuse large B-cell type, with Burkitt lymphomas comprising 25% and other histologies a much smaller proportion.

For patients with relapses, solid evidence points to the safety and utility of hematopoietic-cell transplantation as a salvage modality.

Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the genesis of previously rare or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.

[MeSH-major] Lymphoma, AIDS-Related / therapy

[MeSH-minor] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Transplantation. Humans. Lymphoproliferative Disorders / therapy. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16099881.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 100

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma].

Abdominal CT scan showed a large mass in the ascending colon.

Colonoscopy was performed and histological examination of the colon tumor revealed Burkitt's lymphoma (BL).

In the HAART era, the survival of patients with AIDS-related diffuse large cell lymphoma (DLCL) improved dramatically, whereas the survival of similarly treated patients with AIDS-related BL remained poor.

Our case suggests that intensive chemotherapy with hyper-CVAD/MTX-Ara-C combined with HAART may be well tolerated and effective in AIDS-related BL.

[MeSH-major] Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Colonic Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20379116.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CVAD protocol; EPOCH protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Spectrum of HIV lymphoma 2009.

Lymphomas comprise a large proportion of the malignancies that affect the HIV-infected population in developed countries.

This review summarizes the recent progress made in HIV lymphoma research published in 2009 through January 2010.

RECENT FINDINGS: The majority of investigation in this field has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising.

Rituximab likely improves complete response and possibly overall survival, but may be associated with increased infections in a subset of patients with very low CD4 cell counts.

Risk factors associated with the development of lymphoma include low CD4 cell count and likely cumulative HIV viremia.

SUMMARY: Overall, the outcome for HIV lymphoma continues to improve as insights into the pathophysiology and treatment advance.

[MeSH-major] Antiretroviral Therapy, Highly Active / methods. HIV Infections / therapy. Lymphoma, AIDS-Related / therapy. Stem Cell Transplantation / methods

[MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. CD4 Lymphocyte Count. Combined Modality Therapy. HIV / drug effects. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / therapy. Rituximab

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20442655.001).

[ISSN] 1531-7048

[Journal-full-title] Current opinion in hematology

[ISO-abbreviation] Curr. Opin. Hematol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab

[Number-of-references] 36

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chylous ascites secondary to B-cell non Hodgkin's lymphoma in a patient with the acquired immune deficiency syndrome (AIDS).

In the present article we describe a patient with AIDS and chylous ascites secondary to B-cell non Hodgkin's lymphoma.

The final pathology report was of diffuse, CD20-positive, CD3-negative, Epstein Barr Virus-negative, large B-Cell non Hodgkin's lymphoma.

Five months after the initial diagnosis of lymphoma, the patient relapsed and was treated with high-dose BEAM (carmustine, etoposide, cytosine, arabinoside, melphalan) chemotherapy followed by CD34 stem-cell transplantations salvage therapy.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Chylous Ascites / etiology. Lymphoma, AIDS-Related / complications. Lymphoma, B-Cell / complications

Genetic Alliance. consumer health - Chylous Ascites.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17997372.001).

[ISSN] 1878-3562

[Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

[ISO-abbreviation] Dig Liver Dis

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Oral cavity lymphoma as secondary AIDS-defining neoplasm in a patient on HAART with immune reconstitution.

Lymphomas of the oral cavity are a rare complication of advanced HIV/AIDS disease.

We report the case of a patient with AIDS who developed diffuse large B-cell non-Hodgkins lymphoma of the oral cavity during highly active antiretroviral therapy, with undetectable plasma viral load and immune reconstitution.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mouth Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Oral Cancer.

HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17992417.001).

[ISSN] 0037-8682

[Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical

[ISO-abbreviation] Rev. Soc. Bras. Med. Trop.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] No excess risk of follicular lymphoma in kidney transplant and HIV-related immunodeficiency.

Subtype-specific incidence patterns in populations at high risk of lymphoma offer insight into lymphomagenesis.

The incidence profiles for the 2 most common non-Hodgkin lymphoma subtypes were compared for 2 immunodeficient populations, adults receiving a kidney transplant 1982-2003 (n = 7,730) or diagnosed with human immunodeficiency virus (HIV) infection 1982-2004 (n = 17,175).

National, population-based registries were linked and standardized incidence ratios (SIRs) were computed for each cohort and lymphoma subtype.

Risk of diffuse large B-cell lymphoma was significantly increased after transplantation (SIR 17.83, 95% CI: 13.61-22.95) and after HIV infection (SIR 58.81, 95% CI: 52.59-65.56).

Rates of follicular lymphoma (FL) were neither significantly increased nor decreased in transplant recipients (SIR 0.82, 95% CI: 0.10-2.96) and in people with HIV (SIR 1.25, 95% CI: 0.41-2.91).

The findings argue against an infectious or other immunodeficiency-related etiology for FL and clearly differentiate it from diffuse large B-cell lymphoma.

[MeSH-major] HIV Infections / epidemiology. Kidney Transplantation / statistics & numerical data. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Follicular / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology

Genetic Alliance. consumer health - Follicular Lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - Kidney Transplantation.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20178100.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Grant] United States / NIAID NIH HHS / AI / U01AI069907

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related cancer and severity of immunosuppression in persons with AIDS.

BACKGROUND: The incidence of Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer has been declining among persons with AIDS.

We investigated the association between cancer risk and CD4 cell count among such persons.

METHODS: Data from US AIDS registries were linked to local cancer registry data.

Cancer incidence per 100,000 person-years was determined for the 4-27 months from the onset of AIDS from January 1, 1990, through December 31, 1995--before highly active antiretroviral therapy (HAART) became available--and from January 1, 1996, through December 31, 2002.

The relationships between CD4 count at AIDS onset and cancer incidence were assessed by proportional hazards models.

RESULTS: Among 325,516 adults with AIDS, the incidence of Kaposi sarcoma was lower in 1996-2002 (334.6 cases per 100,000 person-years) than in 1990-1995 (1838.9 cases per 100,000 person-years), and the incidence of non-Hodgkin lymphoma followed a similar pattern (i.e., 390.1 cases per 100,000 person-years in 1996-2002 and 1066.2 cases per 100,000 person-years in 1990-1995).

In 1996-2002, for each decline in CD4 cell count of 50 cells per microliter of blood, increased risks were found for Kaposi sarcoma (hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.33 to 1.50), for central nervous system non-Hodgkin lymphoma subtypes (HR = 1.85, 95% CI = 1.58 to 2.16), and for non-central nervous system diffuse large B-cell lymphoma (HR = 1.12, 95% CI = 1.04 to 1.20) but not for non-central nervous system Burkitt lymphoma (HR = 0.93, 95% CI = 0.81 to 1.06).

After adjustment for age, race, and sex or mode of HIV exposure, the risks for Kaposi sarcoma (RR = 0.22, 95% CI = 0.20 to 0.24) and for non-Hodgkin lymphoma (RR = 0.40, 95% CI = 0.36 to 0.44) were lower in the period of 1996-2002 than in 1990-1995.

CONCLUSIONS: Both before and after HAART was available, CD4 count was strongly associated with risks for Kaposi sarcoma and non-Hodgkin lymphoma but not for cervical cancer and Burkitt lymphoma.

The decreasing incidences of most AIDS-associated cancers in persons with AIDS during the 1990s are consistent with improving CD4 counts after HAART introduction in 1996.

[MeSH-major] Acquired Immunodeficiency Syndrome / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology. Sarcoma, Kaposi / immunology

[MeSH-minor] Adolescent. Adult. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / immunology. Burkitt Lymphoma / virology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Female. Humans. Male. Middle Aged. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / immunology. Uterine Cervical Neoplasms / virology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17565153.001).

[ISSN] 1460-2105

[Journal-full-title] Journal of the National Cancer Institute

[ISO-abbreviation] J. Natl. Cancer Inst.

[Language] eng

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recurrent lymphoma presenting as a penile ulcer in a patient with AIDS.

Penile lymphoma is a rare neoplasm.

We report a 45-year-old man with history of AIDS and previous retroperitoneal lymphoma who presented with painless penile ulceration and multiple inguinal lymphadenopathy.

Fine needle biopsy showed diffuse, large B-cell lymphoma.

We review the literature and discuss this uncommon presentation of lymphoma.

[MeSH-major] Lymphoma, AIDS-Related / pathology. Neoplasm Recurrence, Local / pathology. Penile Diseases / etiology. Penile Diseases / pathology. Penile Neoplasms / etiology. Penile Neoplasms / pathology. Ulcer / etiology. Ulcer / pathology

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16150237.001).

[ISSN] 1087-2108

[Journal-full-title] Dermatology online journal

[ISO-abbreviation] Dermatol. Online J.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 13

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Pathology of AIDS-related lymphadenopathy: a study of 18 biopsy cases].

OBJECTIVE: To study the clinicopathologic features of acquired immunodeficiency syndrome (AIDS)-related lymphadenopathy and to elucidate the salient features helpful in achieving a correct pathologic differentiated diagnosis.

METHODS: Eighteen cases of AIDS-related lymphadenopathy were retrieved from the files of the First Affiliated Hospital of Guangxi Medical University from 2001 to 2004.

The remaining patient was complicated with diffuse large B-cell lymphoma.

CONCLUSIONS: When presented in early stages, AIDS-related lymphadenopathy may be overlooked, especially in routine pathology practice.

Florid infection with Penicillium marneffei is also considered as an important predictor for underlying AIDS.

Thorough understanding of morphologic features of AIDS-related lymphadenopathy, including possible co-infection, is essential in arriving at the correct diagnosis.

[MeSH-major] AIDS-Related Complex / pathology. AIDS-Related Opportunistic Infections / pathology. Lymph Nodes / pathology

[MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Mycobacterium / isolation & purification. Mycobacterium Infections / microbiology. Mycobacterium Infections / pathology. Mycoses / microbiology. Mycoses / pathology. Penicillium / isolation & purification. Retrospective Studies

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16545184.001).

[ISSN] 0529-5807

[Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology

[ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status.

BACKGROUND: The pathologic heterogeneity of AIDS related lymphomas (ARL) reflects several pathogenic mechanisms: chronic antigenic stimulation, Epstein-Barr virus (EBV) infection, and genomic abnormalities.

Most chromosomal regions affected in HIV-related lymphoma were similar to those already reported in HIV-negative lymphomas.

[MeSH-major] Epstein-Barr Virus Infections / genetics. Lymphoma, AIDS-Related / genetics

[MeSH-minor] Adult. Aged. Burkitt Lymphoma / complications. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Chromosome Aberrations. Chromosomes, Human / genetics. Clone Cells / immunology. DNA, Viral / genetics. Female. Genes, Viral / genetics. Genes, Viral / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / immunology. Male. Middle Aged. Nucleic Acid Hybridization / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17117014.001).

[ISSN] 0269-9370

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Viral

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapy-related acute myeloid leukemia following HIV-associated lymphoma.

In the highly active antiretroviral therapy era, an increasingly large number of HIV-infected patients are developing non- AIDS-defining cancers (NADCs).

As patients survive longer, long-term therapy-related complications take on greater importance.

Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.

With the diagnosis of therapy-related acute myeloid leukemia (AML) secured, he began induction chemotherapy with idarubicin and cytarabine.

Through a literature search, we were able to identify 4 additional cases of therapy-related AML in AIDS patients following chemotherapy for lymphomas.

The median age of these patients at the time of AML diagnosis was 39 years (range, 33-59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11-48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2-16 weeks).

With many HIV-infected patients surviving alkylator and topoisomerase inhibitor-based treatment and radiation therapy for AIDS-defining cancers and NADCs, long-term follow-up for therapy-related complications assumes greater importance.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - Leukemia, Myeloid.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19717383.001).

[ISSN] 1938-0712

[Journal-full-title] Clinical lymphoma & myeloma

[ISO-abbreviation] Clin Lymphoma Myeloma

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Activation of mTORC1 signaling pathway in AIDS-related lymphomas.

Using immunohistochemistry with antibodies against the phosphoserine residues in both S6rp and 4E binding protein 1, we identified the activation of the mammalian target of rapamycin (mTORC)1 pathway in 29 cases of AIDS-related lymphoma.

These cases represented a diverse spectrum of histological types of non-Hodgkin lymphoma (24 cases) and classic Hodgkin lymphoma (five cases).

We also found that in B-cell lines that represent diffuse large B-cell lymphoma, Burkitt lymphoma, Epstein-Barr virus-infected lymphocytes, and human herpesvirus 8-positive primary effusion lymphoma, inhibitors of Syk, MEK, and, seemingly, phosphoinositide 3 kinases suppressed mTORC1 activation, in particular when these inhibitors were used in combination.

These findings indicate that AIDS-related lymphoma and other histologically similar types of lymphomas that are derived from transformed B lymphocytes may display clinical responses to inhibitors that directly target mTORC1 or, possibly, upstream activators of the mTORC1 pathway.

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Transpl Int. 2003 Mar;16(3):202-6 [12664217.001]

[Cites] EMBO J. 2002 Aug 1;21(15):4070-80 [12145207.001]

[Cites] J Biol Chem. 2003 Jun 13;278(24):21960-71 [12668683.001]

[Cites] J Biol Chem. 2003 Sep 26;278(39):37288-96 [12867426.001]

[Cites] Biochimie. 2003 Aug;85(8):763-9 [14585543.001]

[Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]

[Cites] Pediatr Transplant. 2004 Jun;8(3):243-8 [15176961.001]

[Cites] J Biol Chem. 1991 Aug 15;266(23):14846-9 [1869521.001]

[Cites] J Biol Chem. 1992 Apr 25;267(12):8613-9 [1569106.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9107-11 [1409610.001]

[Cites] J Biol Chem. 1993 Jul 25;268(21):15900-5 [8340414.001]

[Cites] J Biol Chem. 1993 Nov 15;268(32):24442-8 [8226994.001]

[Cites] J Biol Chem. 1994 Feb 25;269(8):5918-25 [8119935.001]

[Cites] J Immunol. 1994 Jun 1;152(11):5429-37 [8189062.001]

[Cites] EMBO J. 1996 Oct 1;15(19):5256-67 [8895571.001]

[Cites] Immunol Lett. 1999 Jun 1;68(2-3):301-9 [10424436.001]

[Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]

[Cites] J Virol. 2005 May;79(9):5499-506 [15827164.001]

[Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]

[Cites] J Biol Chem. 2005 May 20;280(20):19937-47 [15760907.001]

[Cites] Nephrol Dial Transplant. 2005 Aug;20(8):1748-51 [15919698.001]

[Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]

[Cites] Microsc Res Tech. 2005 Nov;68(3-4):168-75 [16276515.001]

[Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]

[Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]

[Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]

[Cites] Br J Cancer. 2006 Jan 30;94(2):195-9 [16404421.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466-71 [16567633.001]

[Cites] Am J Kidney Dis. 2006 May;47(5):e67-72 [16632009.001]

[Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]

[Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]

[Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]

[Cites] J Biol Chem. 2006 Sep 15;281(37):26904-13 [16816403.001]

[Cites] Oncogene. 2006 Oct 16;25(48):6347-60 [17041621.001]

[Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]

[Cites] Lab Invest. 2007 Jan;87(1):29-39 [17075574.001]

[Cites] Transplant Proc. 2007 May;39(4):1267-71 [17524950.001]

[Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]

[Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]

[Cites] Transplant Proc. 2007 Jul-Aug;39(6):2036-7 [17692685.001]

[Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]

[Cites] Blood. 2008 Feb 15;111(4):2181-9 [18025151.001]

[Cites] Transpl Int. 2008 Jun;21(6):605-8 [18282244.001]

[Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]

[Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]

[Cites] Cancer Res. 2000 Jul 1;60(13):3504-13 [10910062.001]

[Cites] Transplantation. 2003 May 27;75(10):1710-7 [12777861.001]

(PMID = 19608873.001).

[ISSN] 1525-2191

[Journal-full-title] The American journal of pathology

[ISO-abbreviation] Am. J. Pathol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA089194; United States / NIDCR NIH HHS / DE / R01 DE017337; United States / NCI NIH HHS / CA / R01-CA89194; United States / NIDCR NIH HHS / DE / R01-DE-017337

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Phospho-Specific; 0 / Multiprotein Complexes; 0 / Proteins; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 17885-08-4 / Phosphoserine; EC 2.7.1.1 / TOR Serine-Threonine Kinases

[Other-IDs] NLM/ PMC2716976

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [HIV-related multiple non-Hodgkin lymphomas].

He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).

We diagnosed double lymphomas related to AIDS.

Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Stomach Cancer.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19047787.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Unusual case of plasmablastic non-Hodgkin's lymphoma located in the liver. First case reported in an AIDS patient.

Plasmablastic lymphoma is a rare and a relatively new entity that was first described in the jaws and the oral cavity of HIV-AIDS patients.

We report a case of plasmablastic lymphoma involving the liver in an AIDS patient.

Plasmablastic lymphoma is considered a diffuse large B-cell lymphoma with a unique phenotype and predilection for the oral cavity.

The smears showed a dense infiltrate composed by atypical lymphocytes with numerous plasmocytes expressing the plasma cell markers MUM-1 and CD138 and negative for the B-cell markers CD3, CD20 and CD45.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Liver Cancer.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19841505.001).

[ISSN] 1665-2681

[Journal-full-title] Annals of hepatology

[ISO-abbreviation] Ann Hepatol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Mexico

[Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Syndecan-1; 0 / interferon regulatory factor-4

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression.

HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.

Due to their aggressive nature, AIDS-related lymphomas (ARL) can also be more difficult to classify.

To aid in case classification and identify key pathogenetic events in ARL, we analyzed gene expression data and somatic DNA copy number changes by high-resolution array comparative genomic hybridization in tumors from 20 B-cell derived ARL (B-ARL) patients.

Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.

[MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20216076.001).

[ISSN] 1944-7884

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.

Non-Hodgkin's lymphoma (NHL) remains an important complication of associated HIV infection despite advances in antiretroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined.

Patients with aggressive histology HIV-related NHL who were previously untreated with chemotherapy, and who had no active opportunistic infection were eligible for the study.

Forty-seven patients were enrolled, most with diffuse large-cell or immunoblastic NHL.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. Filgrastim .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16216784.001).

[ISSN] 1387-2656

[Journal-full-title] Biotechnology annual review

[ISO-abbreviation] Biotechnol Annu Rev

[Language] eng

[Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; VACOP-B protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient.

He was diagnosed with diffuse large B cell lymphoma (DLBCL) by a biopsy of the inguinal lymph node.

[MeSH-major] Antigens, Neoplasm / analysis. Genes, myc. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Syndecan-1 / analysis. Translocation, Genetic

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - HIV.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19336959.001).

[ISSN] 1349-7235

[Journal-full-title] Internal medicine (Tokyo, Japan)

[ISO-abbreviation] Intern. Med.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; P9G3CKZ4P5 / Ganciclovir; VAD I protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recreational amphetamine use and risk of HIV-related non-Hodgkin lymphoma.

The results of many laboratory studies suggest that amphetamine use may lead to altered immune function and cytokine expression, both of which are implicated in HIV-related lymphomagenesis.

We examined the hypothesis that use of amphetamines modifies risk of non-Hodgkin lymphoma (NHL) in HIV-infected men in the Multicenter AIDS Cohort Study.

Similar associations were observed when we separately examined systemic NHL and diffuse large B-cell lymphoma.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Eur J Epidemiol. 2004;19(6):585-7 [15330132.001]

[Cites] Immunology. 2004 Apr;111(4):357-67 [15056370.001]

[Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]

[Cites] J Acquir Immune Defic Syndr. 1989;2(1):77-83 [2918462.001]

[Cites] Life Sci. 1991;49(16):PL107-12 [1910138.001]

[Cites] Immunopharmacol Immunotoxicol. 1994 Feb;16(1):1-21 [8169319.001]

[Cites] Life Sci. 1996;58(2):PL 29-33 [8606616.001]

[Cites] Am J Epidemiol. 1996 Feb 15;143(4):374-9 [8633621.001]

[Cites] Epidemiology. 1996 Mar;7(2):131-9 [8834551.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jul 1;15(3):211-22 [9257656.001]

[Cites] Br J Cancer. 1997;76(11):1532-7 [9400954.001]

[Cites] Immunopharmacology. 1998 Jan;38(3):253-60 [9506825.001]

[Cites] J Neuroimmunol. 1998 Mar 15;83(1-2):133-8 [9610681.001]

[Cites] J Neuroimmunol. 1998 Mar 15;83(1-2):139-47 [9610682.001]

[Cites] Mem Inst Oswaldo Cruz. 1998 May-Jun;93(3):373-81 [9698872.001]

[Cites] AIDS Educ Prev. 1999 Jun;11(3):232-42 [10407457.001]

[Cites] AIDS Read. 2004 Nov;14(11):605-17 [15570672.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] Scand J Infect Dis. 2005;37(6-7):493-6 [16012010.001]

[Cites] Int J Obes (Lond). 2005 Oct;29(10):1267-74 [15997248.001]

[Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]

[Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] PLoS Med. 2006 Nov;3(11):e438 [17121449.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):392-5 [17337642.001]

[Cites] Int J Cancer. 2007 Oct 1;121(7):1564-70 [17443495.001]

[Cites] Subst Use Misuse. 2007;42(10):1613-28 [17918031.001]

[Cites] AIDS Care. 2007 Oct;19(9):1134-40 [18058397.001]

[Cites] AIDS. 2008 Jan 30;22(3):357-65 [18195562.001]

[Cites] Lancet. 2008 Feb 16;371(9612):569-78 [18280327.001]

[Cites] J Immunol. 2000 Jun 15;164(12):6461-6 [10843702.001]

[Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]

[Cites] Lancet. 2000 Jul 22;356(9226):291-6 [11071184.001]

[Cites] J Pharmacol Exp Ther. 2001 Jan;296(1):207-15 [11123382.001]

[Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]

[Cites] Life Sci. 2001 Nov 2;69(24):2931-41 [11720096.001]

[Cites] Ann N Y Acad Sci. 2002 Jun;965:421-33 [12105117.001]

[Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]

[Cites] J Infect Dis. 2003 Feb 15;187(4):700-4 [12599091.001]

[Cites] J Leukoc Biol. 2003 Oct;74(4):486-96 [12960289.001]

[Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]

[Cites] J Pharmacol Exp Ther. 2004 Apr;309(1):285-92 [14722327.001]

[Cites] AIDS Care. 2004 Nov;16(8):1036-47 [15511735.001]

(PMID = 19011979.001).

[ISSN] 1573-7225

[Journal-full-title] Cancer causes & control : CCC

[ISO-abbreviation] Cancer Causes Control

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIDA NIH HHS / DA / R01 DA008254-12; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCI NIH HHS / CA / P50 CA096888-05; United States / NIDA NIH HHS / DA / R01 DA08254; United States / NIDA NIH HHS / DA / DA003018-18; United States / NIDA NIH HHS / DA / DA008254-12; United States / NIDA NIH HHS / DA / R37 DA003018; United States / NIDA NIH HHS / DA / R37 DA03018; United States / NIDA NIH HHS / DA / R37 DA003018-21; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCI NIH HHS / CA / P50 CA096888-01; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P50CA096888; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIDA NIH HHS / DA / R37 DA003018-18; United States / NIDA NIH HHS / DA / DA008254-06; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIDA NIH HHS / DA / DA003018-21; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIDA NIH HHS / DA / R01 DA008254; United States / NCI NIH HHS / CA / CA096888-01; United States / NIDA NIH HHS / DA / R01 DA008254-06; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NCI NIH HHS / CA / P50 CA096888

[Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Street Drugs; CK833KGX7E / Amphetamine

[Other-IDs] NLM/ NIHMS192303; NLM/ PMC2862618